Fractional Flow Reserve–Guided Complete vs Culprit-Only Revascularization in Non–ST-Elevation Myocardial Infarction and Multivessel Disease
JAMA · 11.11.2025 · 334 (18) · 1628
DOI: 10.1001/jama.2025.16189 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift JAMA, erschienen am 11.11.2025. Verfasst von Tobias F S Pustjens und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Zuyderland Medical Centre, Heerlen, the Netherlands. Hauptthemen laut MEDLINE: Coronary Artery Disease, Fractional Flow Reserve, Myocardial, Myocardial Revascularization, Non-ST Elevated Myocardial Infarction. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance The benefits of fractional flow reserve (FFR)–guided complete coronary revascularization in patients with non–ST-segment elevation myocardial infarction (NSTEMI) and multivessel disease remain unclear.
Objective
To compare FFR-guided complete revascularization of nonculprit lesions vs culprit-only revascularization in patients with NSTEMI and multivessel disease. Design, Setting, and Participants This prospective, investigator-initiated, multicenter, international randomized clinical trial was conducted at 9 hospitals in Europe. Patients with NSTEMI and multivessel disease who had successful revascularization of the culprit lesion were enrolled between June 2018 and July 2024, and final follow-up was completed on July 21, 2025. The analysis was conducted on July 28, 2025. Eligibility criteria included the presence of at least 1 stenosis of at least 50% in a nonculprit lesion amendable for revascularization.
Intervention
Patients were randomized to receive either FFR-guided complete or culprit-only revascularization during the index procedure. Staged revascularization within 6 weeks after the index procedure was allowed in the culprit-only group. Main Outcomes and Measures The primary outcome was a composite of all-cause death, nonfatal myocardial infarction, any revascularization, and stroke at 1 year. Key secondary outcomes included individual components of the primary outcome, net adverse clinical events, all-cause death or nonfatal myocardial infarction, cardiac rehospitalization, and bleeding events.
Results
Among 478 randomized patients (mean [SD] age, 65.9 [10.6] years; 347 [72.9%] males), 240 were randomized to receive FFR-guided complete revascularization and 238 were randomized to receive culprit-only revascularization, with crossover occurring in 7 patients in the culprit-only group. The primary outcome occurred in 13 patients (5.5%) in the FFR-guided complete revascularization group vs 32 patients (13.6%) in the culprit-only group (hazard ratio [HR], 0.38 [95% CI, 0.20-0.72]; P = .003). Rates of any revascularization (3.0% vs 11.5%; HR, 0.24 [95% CI, 0.11-0.56]; P < .001) and net adverse clinical events (6.3% vs 15.3%; HR, 0.39 [95% CI, 0.21-0.70]; P = .002) were also significantly lower in the complete revascularization group, while there were no significant differences in the remaining secondary outcomes. Conclusion and Relevance FFR-guided complete revascularization during the index procedure resulted in a significant reduction in the composite of all-cause death, nonfatal myocardial infarction, any revascularization, and stroke at 1 year. This was mainly driven by reduced repeat revascularization. Trial Registration ClinicalTrials.gov Identifier: NCT03562572
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Cardiology, Zuyderland Medical Centre, Heerlen, the Netherlands.
- Department of Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, the Netherlands.
- Department of Cardiology, Maastricht University Medical Centre, Maastricht, the Netherlands.
- Department of Cardiology, Radboud University Medical Centre, Nijmegen, the Netherlands.
- Invasive Cardiology Division, Internal Medicine Department, University of Szeged, Szeged, Hungary.
- Hungarian Institute of Cardiology, Budapest, Hungary.
Zitieren
APA
Pustjens, T. F. S., Veenstra, L., Camaro, C., Ruiters, A. W., Lux, Á., Ruzsa, Z., Piroth, Z., Ilhan, M., Vainer, J., Gho, B., Winkler, P. J. C., Stein, M., Theunissen, R. A. L. J., Kala, P., Polad, J., Berta, B., Gabrio, A., van Royen, N., van 't Hof, A. W. J., & Rasoul, S. (2025). Fractional Flow Reserve–Guided Complete vs Culprit-Only Revascularization in Non–ST-Elevation Myocardial Infarction and Multivessel Disease. JAMA, 334(18), 1628. https://doi.org/10.1001/jama.2025.16189
Vancouver
Pustjens TFS, Veenstra L, Camaro C, Ruiters AW, Lux Á, Ruzsa Z, et al. Fractional Flow Reserve–Guided Complete vs Culprit-Only Revascularization in Non–ST-Elevation Myocardial Infarction and Multivessel Disease. JAMA. 2025;334(18):1628. doi:10.1001/jama.2025.16189
BibTeX
@article{Pustjens2025,
author = {Pustjens, Tobias F S and Veenstra, Leo and Camaro, Cyril and Ruiters, Alexander W and Lux, Árpad and Ruzsa, Zoltán and Piroth, Zsolt and Ilhan, Mustafa and Vainer, Jindrich and Gho, Ben and Winkler, Patty J C and Stein, Mera and Theunissen, Ralph A L J and Kala, Petr and Polad, Jawed and Berta, Balázs and Gabrio, Andrea and van Royen, Niels and van 't Hof, Arnoud W J and Rasoul, Saman},
title = {Fractional Flow Reserve–Guided Complete vs Culprit-Only Revascularization in Non–ST-Elevation Myocardial Infarction and Multivessel Disease},
journal = {JAMA},
year = {2025},
volume = {334},
number = {18},
pages = {1628},
doi = {10.1001/jama.2025.16189}
}
EUVIMED